News Focus
News Focus
Followers 309
Posts 37472
Boards Moderated 1
Alias Born 11/14/2013

Re: None

Monday, 04/24/2017 7:05:35 PM

Monday, April 24, 2017 7:05:35 PM

Post# of 827780
Let's just say we were fully diluted at 260 million shares outstanding.

Five billion / 250 million = 20 PPS (Note: 300 million fully diluted would = 16.67)
Five billion is the price some 'round here balked at 20 months ago. I think Five billion is very low if DCVax-l succeeds.

Ten billion / 250 million = 40 pps
Twenty billion = 80 pps This is about the price range Larry thinks the stock could run to if successful with the DCVax-L trial .

The company's potential value should be based upon far more than DCVax-L as a monotherapy for various indications. It should take into account DCVax-Direct. Combinations with Direct and L, and potential licensing.

I could care less what bears think right now. The shorts won the price per share battle. They helped India win the race to commercialization. Congrats. Shorts are very very rich. The question is, can the science come through.

Pyrr's unsubstantiated claims of certainty do not change the science. No one on the outside objectively knows what is going to happen.

Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News